Patent application number | Description | Published |
20090215754 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS - The present invention relates to methods and compositions for treating neuropathic pain and neuropsychiatric disorders by administering agents that are effective in reducing the effective amount, inactivating, and/or inhibiting the activity of a Na | 08-27-2009 |
20090258844 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERS OF THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS - The present invention relates to methods and compositions for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, one aspect of the present invention relates to methods and materials for treating seizure and seizure disorders, epilepsy, status epilepticus, migraine, spreading depression, intracranial hypertension; for treating the pathophysiological effects of head trauma, stroke, ischemia and hypoxia; for treating or protecting from the pathophysiological effects of neurotoxic agents such as ethanol; and for treating neuropsychiatric disorders and central nervous system edema by administering agents that modulate ionic concentrations and/or ionic gradients in the brain, particularly ion-dependent or cation-chloride cotransporter antagonists. Electrolyte cotransport antagonists and combinations of such compositions with other agents for treating various conditions are disclosed. | 10-15-2009 |
20120108640 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS - The present invention relates to methods and compositions for treating neuropathic pain and neuropsychiatric disorders by administering agents that are effective in reducing the effective amount, inactivating, and/or inhibiting the activity of a Na | 05-03-2012 |
20120234721 | DIURETIC AND DIURETIC-LIKE COMPOUND ANALOGS - The present invention provides compounds that are effective in treating central nervous system disorders and maintaining normal brain function. Methods of making and using the compounds are also provided. | 09-20-2012 |
20140066504 | ANALOGS AND PRODRUGS OF BUMETANIDE; COMPOSITIONS AND METHODS OF USE - Novel analogs and prodrugs of the loop diuretic bumetanide are described. Pharmaceutical compositions containing bumetanide analogs and prodrugs are also described. These analogs and prodrugs are particularly useful for the treatment and/or prophylaxis of conditions that involve the NKCC cotransporter family (NKCC1 and NKCC2), or the KCC cotransporter family (KCC1, KCC2, KCC3, KCC4), or GABAa receptors. Such conditions include, but are not limited to anxiety disorders, epilepsy, migraine, non-epileptic seizures, sleep disorders, obesity, eating disorders, autism, depression, edema, glaucoma, stroke, ischemia, neuropathic pain, addictive disorders, schizophrenia, psychosis, and tinnitus. | 03-06-2014 |
20150080350 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE - The present invention provides bumetanide, analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide, analogs and methods for their use. These analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na | 03-19-2015 |
Patent application number | Description | Published |
20140094934 | CONTROL DEVICE, SYSTEM CONTAINING THE CONTROL DEVICE AND METHOD OF USING THE SAME - Disclosed is a control device for a serial network protocol controller configured to selectively disable control of a parameter of a controllable media device by at least one channel while the serial network protocol controller continues to transmit the at least one channel to the at least on serial network protocol controllable media device. | 04-03-2014 |
20140211424 | HINGED CONNECTOR AND MODULAR VIDEO DISPLAY ASSEMBLY CONTAINING SAME - Disclosed are a hinged connector and a video display assembly containing an attachment panel having a front surface and a back surface, with a video display attached to the front surface and at least one hinged connector attached to the back surface. | 07-31-2014 |
20140301082 | HOUSING HAVING AIR VALVE - Disclosed is a housing includes a housing body and a cap assembly. The cap assembly includes an inner member, an outer member and a resilient compression gasket disposed between the inner and outer members. The inner member has a first valve aperture, the outer member has a second valve aperture and the resilient, compression gasket has a third valve aperture which together form an air valve in the cap assembly. | 10-09-2014 |
20140328052 | LIGHT-EMITTING ASSEMBLY AND LIGHT-EMITTING FLOOR SYSTEM CONTAINING THE SAME - Disclosed is a light-emitting assembly containing a panel having a first side and an opposing second side, a plurality of bores extending from the first side to the second side, an LED light source, such as a printed circuit board, having first side and an opposing second side, the first side of the LED light source adjacent to the side of the panel, the LED light source comprising a plurality of LEDs and a plurality of optical wave guides, each wave guide having a first end and a second end, the first end disposed in one of the bores and the second end optically connected to one of the LEDs. | 11-06-2014 |
20140368349 | SENSORY ELEMENT PROJECTION SYSTEM AND METHOD OF USE - Disclosed is an electromagnetic signal projector configured to transmit a pixelated signal across a projection field. The electromagnetic signal projector includes a transmitter configured to transmit a pixelated signal across a projection field and a plurality of individual sensory modules, where each sensory module includes at least one sensory element having at least two states and the sensory modules are configured for bringing the at least one sensory element into one of its states in response to the pixelated signal. | 12-18-2014 |
Patent application number | Description | Published |
20090030366 | SELF-ADMINISTRATION INJECTION SYSTEM - Self-injection system allows a user to inject a drug from a cartridge carrying unique identification information, into any one of a plurality of injection sites. Tissue at each injection site is associated with at least one injection parameter, such as flow-rate, that is different for each site. A scanner reads the identification information of the cartridge and cooperates with a central processing unit to determine the validity of the drug in order to permit an injection procedure to commence. The central processing unit has a memory for storing the different injection parameters and controls a drive unit for driving fluid from the cartridge and through a needle into the selected tissue, at the injection parameter that is associated with the user selected tissue for the injection. | 01-29-2009 |
20090326482 | Computer Controlled Drug Delivery System with Dynamic Pressure Sensing - Apparatus administers dental anesthetic to intraligamentary tissue with a drive unit and handpiece with injection needle connected by flexible tube to the unit. The drug is passes to the tissue at an instantaneous pressure at the needle tip that varies due to placement. A minimum threshold pressure is desired for administering the drug to the tissue. A practitioner moves the handpiece to insert the needle tip near the intraligamentary tissue and the instantaneous pressure is sensing or calculating. An auditory ascending signal indicates when the instantaneous pressure is rising, and when the instantaneous pressure reaches the threshold pressure a perceptible auditory specific signal indicates the practitioner has moved the tip into intraligamentary tissue. The tip is then maintained for supplying a selected dosage of the drug. Another auditory signal notifies the practitioner that the instantaneous pressure is declining or fluctuating before reaching the minimum threshold pressure. | 12-31-2009 |
20120245560 | MULTI-VESSEL COMPUTER CONTROL DRUG DELIVERY - Apparatus for combining and subcutaneously injecting a mixture of drug and other liquid such as a buffering solution, uses cartridges with cylinders containing the drug and other liquid, and pistons pushable toward discharge ends of the cylinders for discharging the liquids. A drive unit housing with motor therein is activated by computer to linearly move a motor plunger. A multiple cartridge holder receives cartridges with the drug and other liquid and has a mixing chamber with inlets connected to the discharge ends for receiving a mixture of drug and other liquids. Micro-tubing is connected to an outlet of the chamber and has a handpiece with subcutaneous injection needle at its opposite end for receiving and injecting the mixture. Plural cartridge plungers are engages via a motion transmission to the motor plunger and move into open ends of the cartridges to push the pistons and discharge liquids from the cartridges into the mixing chamber. | 09-27-2012 |
20130189646 | METHOD AND APPARATUS FOR RECORDING SPATIAL GINGIVAL SOFT TISSUE RELATIONSHIP TO IMPLANT PLACEMENT WITHIN ALVEOLAR BONE FOR IMMEDIATE-IMPLANT PLACEMENT - A dental implant has a hollow shell with outer bio-compatible surface for engaging a soft tissue socket left in gingival tissue after a tooth has been extracted, to promote healing. The shell tapers outwardly from a first to a second perimeter, the second perimeter being asymmetrically scalloped with opposite distal and mesial peaks and opposite lingual and facial valleys between the peaks. A dental implant in the bone socket left after tooth extraction is rigidly connected to a temporary post, the temporary post extending in the shell. The shell engages against the soft tissue socket without gaps and without requiring alignment between the shell and implant axes. | 07-25-2013 |
20130288202 | SOFT TISSUE PRESERVATION TEMPORARY (SHELL) IMMEDIATE-IMPLANT ABUTMENT WITH BIOLOGICAL ACTIVE SURFACE - An immediate dental implant shell has outer, multiple zones for engaging a soft tissue socket left immediately after tooth extraction from a bone socket. The zones have combinations of different biologic agents, macro- or micro-geometric, or micro- or macro-morphology irregularities to better engage gingival sulcus, junctional epithelium and dento-gingival fiber zones of the soft tissue socket. The shell may also have various guide markings and projections to aide drilling of the implant hole in the bone socket. A dental implant is placed in the drilled implant hole before or after the shell has been placed in the soft tissue socket, and has an axis that is independent of the shell axis so the shell and implant both sit in optimum positions in their respective soft and bone sockets. | 10-31-2013 |
20140012226 | DRUG INFUSION WITH PRESSURE SENSING AND NON-CONTINUOUS FLOW FOR IDENTIFICATION OF AND INJECTION INTO FLUID-FILLED ANATOMIC SPACES - An automatic injection apparatus uses non-continuous fluid-flow of drugs to identify an intended injection site and includes a drive mechanism, a sensor and a controller for establishing fluid flow and pressure and preventing fluid flow until the pressure drops below a predetermined threshold. The pressure threshold is determined based on an internal pressure generated during an injection and more fluid will not flow until it drops below a predetermined pressure. An injection is performed to establish an initial pressure threshhold and then to stop the fluid flow into a patient until the pressure drops below a predetermined pressure which allows fluid flow to resume, thus identifying a fluid filled tissue space. The initial pressure threshold is used as a control parameter to a microprocessor below which controls the rate of injection. Fluid flows below certain pressures are also used to identify a specific location within the body during injections. | 01-09-2014 |
Patent application number | Description | Published |
20130102951 | CSF SHUNT FLOW ENHANCER, METHOD FOR GENERATING CSF FLOW IN SHUNTS AND ASSESSMENT OF PARTIAL AND COMPLETE OCCLUSION OF CSF SHUNT SYSTEMS - An apparatus capable of generating flow in cerebrospinal fluid (CSF) shunt systems by vibrating the shunt, tubing or shunt valve dome, or applying cyclical pressure to the various parts of the shunt system. A method of generating flow and method of using the apparatus in shunt patency assessment, for example, hydraulic resistance assessment, is also disclosed. The apparatus allows, in conjunction with a thermal dilution method or radionuclide method, a quick CSF shunt patency assessment based upon CSF shunt resistance and not upon CSF flow or intracranial pressure (ICP) separately. This provides a more objective measure of shunt obstruction compared to other methods. Furthermore, the apparatus can be used to enhance flow in shunts, identify partial occlusion before symptoms occur, differentiate between patent, partially-occluded and occluded shunts. The apparatus can be used to generate flow in shunts if there is a need to lower ICP or move drugs administered via an injection chamber or a shunt dome. | 04-25-2013 |
20130109998 | REAL TIME CSF FLOW MEASUREMENT SYSTEM & METHOD | 05-02-2013 |
20130247644 | IMPLANTABLE PRESSURE SENSOR - A pressure sensor that is implantable within a living being that wirelessly provides pressure data within the living being to a wireless receiver. The pressure sensor includes an elastic membrane to which at least one capacitive actuator is coupled for applying a known force to the membrane to determine membrane characteristics. The pressure sensor includes a force transducer contacting the membrane for determining the pressure within the living being and which includes an internal calibrating force mechanism. This calibrating force mechanism permits force transducer displacement away from the membrane where a zero force transducer reading is taken and then applying a calibrating force and taking another reading. From these two points, a force transducer characteristic is derived and, along with membrane characteristics, an accurate pressure within the living being is obtained from the sensor. An alternative embodiment replaces the capacitive actuators with a known mass and an external vibratory source. | 09-26-2013 |
20150045717 | Real Time CSF Flow Measurement System & Method - A system for measuring quantitative CSF flow in shunt tubing implanted under the skin. The system includes an array of thermo-sensors clustered in three sections, cooling device, placed on the skin surface and an associated data acquisition and analysis device. Two sensor sections are placed over the shunt on the skin and measure real time temperature responses related to CSF movement. One array placed adjacent the cooling device collects data on thermal properties of skin including skin thermal conductivity, specific heat, diffusivity, perfusion, and thermal inertia. The method involves assessing thermal properties of skin and measuring CSF flow in shunt tubing. The method is useful for shunt patency assessment, CSF valve adjustment procedures and CSF flow measurements related to CSF over drainage. Alternatively, only one section of sensors need be used when determining relative CSF flow, without the need to determine thermal skin properties and by applying the cooling device continuously. | 02-12-2015 |
Patent application number | Description | Published |
20090104150 | Polymer conjugates of interferon Beta-1a and uses - An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications. | 04-23-2009 |
20090286958 | INTERFERON-BETA FUSION PROTEINS AND USES - A fusion polypeptide is described having the amino acid sequence X-Y-Z, or portion thereof, comprising the amino acid sequence of a glycosylated interferon-beta (X); Y is an optional linker moiety; and Z is a polypeptide comprising at least a portion of a polypeptide other than glycosylated interferon-beta. It is preferred that X is human interferon-beta-1a. Mutants of interferon-beta-1a are also described. | 11-19-2009 |
20150011732 | POLYMER CONJUGATES OF INTERFERON BETA-1A AND USES - An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications. | 01-08-2015 |
Patent application number | Description | Published |
20110046073 | SOLUBLE LYMPHOTOXIN-BETA RECEPTOR FUSION PROTEIN AND METHODS FOR INHIBITING LYMPHOTOXIN BETA-RECEPTOR SIGNALING - This invention relates to compositions and methods comprising “lymphotoxin-β-receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-β.receptor extracellular domain that act as lymphotoxin-β receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-β.receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-β receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-β receptor signalling is provided. | 02-24-2011 |
20120156214 | SOLUBLE LYMPHOTOXIN-BETA RECEPTORS AND ANTI-LYMPHOTOXIN RECEPTOR AND LIGAND ANTIBODIES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF IMMUNOLOGICAL DISEASES - Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signalling and are useful for altering immunological diseases, and particularly antibody mediated immune responses. | 06-21-2012 |
20120263796 | ANTI-VLA-4 RELATED ASSAYS - Methods and apparatus for assaying the level of analytes in a sample, related to VLA-4, are disclosed. A method of decreasing the level of an anti-integrin antibody in a subject is described including a) contacting a biological sample from a subject with a detectable capture agent associated with a substrate, wherein the capture agent can bind an anti-integrin antibody in the sample; b) detecting binding of the capture agent with the level of the anti-integrin antibody; and c) treating the subject with plasma exchange until the level of the anti-integrin antibody in the sample reaches a predetermined level. | 10-18-2012 |